49 Wealth Management’s Nurix Therapeutics NRIX Stock Holding History

49 Wealth Management’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,018	Closed	-$155K	–	260
2026 Q1	$155K	Sell	10,018 -140	-1%	-$2.32K	0.01%	192
2025 Q4	$193K	Sell	10,158 -1,520	-13%	-$21.8K	0.02%	188
2025 Q3	$108K	Buy	+11,678	New	+$121K	0.01%	189
2024 Q2	–	Sell	-12,503	Closed	-$182K	–	167
2024 Q1	$182K	Sell	12,503 -1,185	-9%	-$12.7K	0.04%	118
2023 Q4	$141K	Buy	+13,688	New	+$93.8K	0.04%	115

Other funds holding NRIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

49 Wealth Management's NRIX Position: Q2 2026 in Review

49 Wealth Management sold out of Nurix Therapeutics (NRIX) in Q2 2026, closing a stake of 10,018 shares — an estimated $155K sold.

49 Wealth Management first reported a position in NRIX in Q4 2023 and held it in 5 quarters. The position peaked at $193K in Q4 2025. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

49 Wealth Management reported no remaining Nurix Therapeutics position as of Q2 2026 after selling out during the quarter.
49 Wealth Management sold 10,018 Nurix Therapeutics shares in Q2 2026, an estimated $155K.
49 Wealth Management first reported a position in Nurix Therapeutics in Q4 2023 and held it in 5 quarters.
49 Wealth Management's Nurix Therapeutics position peaked at $193K in Q4 2025.
211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on 49 Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.